Advanced Oncotherapy (LSE:AVO) ROCE % : -21.45% (As of Jun. 2022)

View and export this data going back to 2006. Start your Free Trial

What is Advanced Oncotherapy ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Advanced Oncotherapy's annualized ROCE % for the quarter that ended in Jun. 2022 was -21.45%.

Advanced Oncotherapy ROCE % Historical Data

The historical data trend for Advanced Oncotherapy's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy ROCE % Chart

Advanced Oncotherapy Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

Get a 7-Day Free Trial

-48.56

-55.17

-26.66

-20.24

-21.28

Advanced Oncotherapy Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
ROCE %	Get a 7-Day Free Trial															-18.99	-22.02	-21.91	-24.06	-21.45

Advanced Oncotherapy ROCE % Calculation

Advanced Oncotherapy's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-24.431	/	( ( (122.293 - 17.885)	+	(141.291 - 16.118) )	/ 2 )
	=	-24.431	/	( (104.408	+	125.173)	/ 2 )
	=	-24.431	/	114.7905
	=	-21.28 %

Advanced Oncotherapy's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	-27.072	/	( ( (141.291 - 16.118)	+	(153.173 - 25.954) )	/ 2 )
	=	-27.072	/	( ( 125.173	+	127.219 )	/ 2 )
	=	-27.072	/	126.196
	=	-21.45 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2022) EBIT data.

Advanced Oncotherapy (LSE:AVO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Advanced Oncotherapy ROCE % Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Oncotherapy (LSE:AVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (LSE:AVO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Tenterden Street, Third Floor, London, GBR, W1S 1TE

Website

https://www.avoplc.com

Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.